Michael

Michael Iskra Takes Helm at Cleveland Diagnostics to Accelerate Growth Post-IsoPSA FDA Approval

Cleveland Diagnostics Appoints Michael Iskra as CEO to Accelerate Growth Following FDA Approval of IsoPSA® Assay Cleveland Diagnostics, a pioneering commercial-stage precision oncology company, has announced the appointment of Michael Iskra as its new Chief Executive Officer. With more than…

Read MoreMichael Iskra Takes Helm at Cleveland Diagnostics to Accelerate Growth Post-IsoPSA FDA Approval
Life Sciences

Life Sciences Ontario Announces 2026 Awards Celebrating Excellence and Innovation

Life Sciences Ontario Announces 2026 Awards Celebrating Excellence, Leadership, and Innovation Across the Life Sciences Sector Life Sciences Ontario (LSO) has announced the recipients of the 2026 LSO Awards, recognizing outstanding leadership, innovation, and service across Ontario’s dynamic life sciences…

Read MoreLife Sciences Ontario Announces 2026 Awards Celebrating Excellence and Innovation
CorriXR

CorriXR Therapeutics Publishes New Preclinical Data on Restored Chemosensitivity

CorriXR Therapeutics Publishes Peer-Reviewed Preclinical Study Demonstrating CRISPR-Based NRF2 Editing Restores Chemosensitivity in Treatment-Resistant Solid Tumors CorriXR Therapeutics, an oncology-focused biotherapeutics company developing next-generation genetic medicines to overcome drug resistance in solid tumors, has announced the publication of new peer-reviewed…

Read MoreCorriXR Therapeutics Publishes New Preclinical Data on Restored Chemosensitivity